文献速递消化系统肿瘤

晚期胰腺癌实时基因组分析助力精准医疗

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
PubMed 文献 · Cancer Discov · 2018-06-14

该研究通过活检程序对晚期胰腺导管腺癌(PDAC)患者进行实时全外显子组和RNA测序。在71例患者中,48%检出治疗相关基因组改变,18%检出致病性胚系变异,30%因基因组数据改变临床管理。研究证明实时基因组分析可行且有价值,可指导治疗决策。

要点

  • 48%的晚期PDAC患者检出治疗相关基因组改变。
  • 18%的患者检出致病性胚系变异。
  • 30%的患者因基因组数据改变了临床管理。

核心结论

  • 实时基因组分析在晚期胰腺癌中可行,可识别影响临床管理的相关变异。

研究设计与样本

  • 研究实施活检方案,对晚期PDAC患者进行时效性全外显子组测序和RNA测序,共纳入71例患者。

主要发现

  • 48%(34/71)的患者检出治疗相关基因组改变,18%(13/71)检出致病/可能致病性胚系变异。
  • 30%(21/71)的入组患者因基因组数据改变了临床管理。
  • 2例患者存在致癌性BRAF框内缺失,首次提供该变异对MAPK通路抑制敏感的临床证据。
  • 识别出具有临床相关性的肿瘤/基质基因表达特征。

临床怎么用

  • 对晚期PDAC患者可考虑实施实时基因组分析以指导治疗选择。

局限性

  • 转移性PDAC肿瘤的分子分析因活检标本细胞组成异质性和疾病快速进展而具有挑战性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but molecular characterization is not yet standard in clinical care. We implemented a biopsy protocol to perform time-sensitive whole-exome sequencing and RNA sequencing for patients with advanced PDAC. Therapeutically relevant genomic alterations were identified in 48% (34/71) and pathogenic/likely pathogenic germline alterations in 18% (13/71) of patients. Overall, 30% (21/71) of enrolled patients experienced a change in clinical management as a result of genomic data. Twenty-six patients had germline and/or somatic alterations in DNA-damage repair genes, and 5 additional patients had mutational signatures of homologous recombination deficiency but no identified causal genomic alteration. Two patients had oncogenic in-frame BRAF deletions, and we report the first clinical evidence that this alteration confers sensitivity to MAPK pathway inhibition. Moreover, we identified tumor/stroma gene expression signatures with clinical relevance. Collectively, these data demonstrate the feasibility and value of real-time genomic characterization of advanced PDAC.Significance: Molecular analyses of metastatic PDAC tumors are challenging due to the heterogeneous cellular composition of biopsy specimens and rapid progression of the disease. Using an integrated multidisciplinary biopsy program, we demonstrate that real-time genomic characterization of advanced PDAC can identify clinically relevant alterations that inform management of this difficult disease. Cancer Discov; 8(9); 1096-111. ©2018 AACR.See related commentary by Collisson, p. 1062This article is highlighted in the In This Issue feature, p. 1047.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Aguirre AJ, Nowak JA, Camarda ND, et al. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018. PMID: 29903880. doi:10.1158/2159-8290.CD-18-0275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。